{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:48Z","timestamp":1793948448464,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.xkme.2024.100833","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T03:32:00Z","timestamp":1714102320000},"page":"100833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety"],"prefix":"10.1016","volume":"6","author":[{"given":"Kirk N.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle N.","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarak","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radko","family":"Komers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Trachtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.xkme.2024.100833_bib1","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.xkme.2024.100833_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41581-021-00427-1","article-title":"Therapeutic trials in adult FSGS: lessons learned and the road forward","volume":"17","author":"De Vriese","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"3 suppl 1","key":"10.1016\/j.xkme.2024.100833_bib3","first-page":"S1","article-title":"US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States","volume":"67","author":"Saran","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2024.100833_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fped.2016.00025","article-title":"Changing the paradigm for the treatment and development of new therapies for FSGS","volume":"4","author":"Spino","year":"2016","journal-title":"Front Pediatr"},{"issue":"10","key":"10.1016\/j.xkme.2024.100833_bib5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00467-015-3062-1","article-title":"Recurrent focal segmental glomerulosclerosis after kidney transplantation","volume":"30","author":"Trachtman","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2024.100833_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2024.100833_bib7","article-title":"Early recurrence of focal segmental glomerulosclerosis in kidney transplant recipients: when to consider regifting","volume":"8","author":"Wood","year":"2023","journal-title":"Transpl Rep"},{"issue":"5","key":"10.1016\/j.xkme.2024.100833_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/j.ackd.2014.05.010","article-title":"Permeability factors in focal and segmental glomerulosclerosis","volume":"21","author":"Reiser","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"10.1016\/j.xkme.2024.100833_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2024.100833_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A\u00a0single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2024.100833_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrneph.2015.148","article-title":"Decade in review\u2014genetics of kidney diseases: genetic dissection of kidney disorders","volume":"11","author":"Hildebrandt","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"4S","key":"10.1016\/j.xkme.2024.100833_bib12","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xkme.2024.100833_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.ackd.2014.01.010","article-title":"Treatment of FSGS in children","volume":"21","author":"Sethna","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1016\/j.xkme.2024.100833_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2024.100833_bib15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MNH.0000000000000716","article-title":"Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease","volume":"30","author":"Smeijer","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"10.1016\/j.xkme.2024.100833_bib16","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease","volume":"310","author":"Komers","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"10.1016\/j.xkme.2024.100833_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1358\/dof.2020.45.2.3058863","article-title":"Sparsentan. dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, treatment of focal segmental glomerulosclerosis, treatment of IgA nephropathy","volume":"45","author":"Trachtman","year":"2020","journal-title":"Drugs Future"},{"issue":"4","key":"10.1016\/j.xkme.2024.100833_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-020-04518-2","article-title":"Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition","volume":"36","author":"Benigni","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"10184","key":"10.1016\/j.xkme.2024.100833_bib19","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.xkme.2024.100833_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2024.100833_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.xkme.2024.100833_bib22","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2024.100833_bib23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ekir.2017.02.019","article-title":"Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET)","volume":"2","author":"Komers","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.xkme.2024.100833_bib24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2215\/CJN.04780517","article-title":"An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis","volume":"13","author":"Troost","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2024.100833_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.xkme.2024.100833_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.xkme.2024.100833_bib27","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.xkme.2024.100833_bib28","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.ekir.2023.07.022","article-title":"Implications of complete proteinuria remission at any time in focal segmental glomerulosclerosis: sparsentan DUET trial","volume":"8","author":"Trachtman","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2024.100833_bib29","article-title":"FC 016 sparsentan improves glomerular blood flow and augments protective tissue remodeling in mouse models of focal segmental glomerulosclerosis (FSGS)","volume":"36","author":"Gyarmati","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2024.100833_bib30","doi-asserted-by":"crossref","first-page":"FR","DOI":"10.1681\/ASN.20223311S133a","article-title":"Sparsentan improves glomerular endothelial and podocyte functions and augments protective tissue repair in a mouse model of focal segmental glomerulosclerosis (FSGS) [abstract]","volume":"33","author":"Gyarmati","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1016\/j.xkme.2024.100833_bib31","article-title":"MO255: Sparsentan protects the glomerular basement membrane and glycocalyx, and attenuates proteinuria in a rat model of focal segmental glomerulosclerosis (FSGS) [abstract]","volume":"37","author":"Bedard","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 3","key":"10.1016\/j.xkme.2024.100833_bib32","volume":"37","author":"Nagasawa","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2024.100833_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1681\/ASN.20213210S1459a","article-title":"The dual endothelin angiotensin receptor antagonist (DEARA) sparsentan protects from glomerular hypercellularity and associated immune\/inflammatory gene network activity in a model of IgA nephropathy","volume":"32","author":"Reily","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.xkme.2024.100833_bib34","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ekir.2019.05.031","article-title":"SAT-010 protective effects of sparsentan from proliferative glomerular injury induced by administration of human immune complexes in a murine model of experimental IgA nephropathy","volume":"4","author":"Jenkinson","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.xkme.2024.100833_bib35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/path.6087","article-title":"Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice","volume":"260","author":"Cosgrove","year":"2023","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.xkme.2024.100833_bib36","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2024.100833_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","article-title":"Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis","volume":"77","author":"Troost","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.xkme.2024.100833_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28701","article-title":"Comparing kidney health outcomes in children, adolescents, and adults with focal segmental glomerulosclerosis","volume":"5","author":"Gipson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.xkme.2024.100833_bib39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2024.100833_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100833_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/jm049548x","article-title":"Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics","volume":"48","author":"Murugesan","year":"2005","journal-title":"J\u00a0Med Chem"},{"issue":"10388","key":"10.1016\/j.xkme.2024.100833_bib42","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xkme.2024.100833_bib43","series-title":"Travere Therapeutics announces topline results from two-year primary efficacy endpoint in pivotal phase 3 DUPLEX study\u00a0of sparsentan in focal segmental glomerulosclerosis","year":"2023"},{"issue":"26","key":"10.1016\/j.xkme.2024.100833_bib44","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10417","key":"10.1016\/j.xkme.2024.100833_bib45","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952400044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952400044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T14:47:13Z","timestamp":1717426033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259005952400044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S259005952400044X"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100833","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100833"}}